Alembic Pharma Q1 FY27 Revenue Up 26% to ₹2150 Cr

Alembic Pharmaceuticals reported a resilient Q1 FY27 performance with a 26% year-on-year increase in revenue from operations, reaching ₹2150 Cr. Profit After Tax (PAT) grew by 12% YoY to ₹173 Cr. EBITDA pre-R&D stood at ₹523 Cr, with a margin of 24%. The company saw strong growth in its US Formulation business, up 49% to ₹778 Cr, and a 33% rise in its API business to ₹346 Cr. The India Branded Business grew 7% YoY to ₹642 Cr. Management highlighted broad-based growth driven by volume, new product launches, and execution across key markets. The company also received 10 ANDA approvals and launched 7 new products in the US market during the quarter.